Prospective Trial of Tranexamic Acid in Cardiac Surgery

A Randomized Double-blinded Trial to Explore the Optimum Dose of Tranexamic Acid in Cardiopulmonary Bypass Cardiac Surgery

Tranexamic acid, an antifibrinolytic drug, is wildly used in cardiac surgeries to decrease perioperative bleeding and allogenic transfusion. But the optimum dose of tranexamic acid is still unknown. We use three different doses to find which is the optimum dose of tranexamic acid in cardiopulmonary bypass cardiac surgery.

Inclusion Criteria:

• Noncyanotic congenital heart disease patients requiring cardiac surgeries under cardiopulmonary bypass
• Rheumatic or recessive valvular disease patients requiring valvular repair or replacement under cardiopulmonary bypass
• Coronary artery disease patients requiring coronary artery bypass graft under cardiopulmonary bypass

Exclusion Criteria:

• Non-primary and emergency cardiac surgery
• Disorder in coagulation function before surgery
• Anemia before surgery
• Definite liver and renal dysfunction
• History of stroke
• Pregnancy and lactation
• Disabled in spirit or law
• Fatal conditions such as cancer